- Home
- IOBT vs BOLD Comparison
IOBT vs BOLD Comparison
Compare IOBT & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IOBT | BOLD |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.6M | 25.7M |
| IPO Year | 2021 | 2024 |
Fundamental Metrics
Financial Performance| Metric | IOBT | BOLD |
|---|---|---|
| Price | $0.20 | $1.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $2.25 | ★ $4.00 |
| AVG Volume (30 Days) | ★ 890.1K | 63.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 26.77 | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.21 | $0.96 |
| 52 Week High | $2.79 | $1.78 |
Technical Indicators
Market Signals| Indicator | IOBT | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 25.94 | 39.80 |
| Support Level | N/A | $1.10 |
| Resistance Level | $0.40 | $1.20 |
| Average True Range (ATR) | 0.03 | 0.03 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 4.92 | 0.00 |
Price Performance
Historical ComparisonAbout IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.